6-methyl-8-phenylquinoline | 1275591-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-methyl-8-phenylquinoline
• CAS: 1275591-23-5
• 化学式: C₁₆H₁₃N
• 分子量: 219.286
• InChiKey: LRGXUYUQZWZCDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-甲基喹啉 、 溴苯 在 dirhodium tetraacetate 、 1,3-双(2,4,6-三甲基苯基)氯化咪唑 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以87%的产率得到6-methyl-8-phenylquinoline
  参考文献：
  名称：

  Rh(NHC)-Catalyzed Direct and Selective Arylation of Quinolines at the 8-Position

  摘要：

  A new catalytic protocol for the regioselective direct arylation of quinoline derivatives at the 8-position has been developed. The reaction is catalyzed by a Rh(NHC) system, and the choice of the NHC ligand was most important for achieving high reactivity and selectivity.

  DOI：

  10.1021/ja111670s

文献信息

• Organic light-emitting device
  申请人：SAMSUNG DISPLAY CO., LTD.

  公开号：US10826000B2

  公开（公告）日：2020-11-03

  An organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, wherein the emission layer includes a first host and a dopant, the first host is represented by one selected from Formulae 1 and 2, and the dopant is represented by Formula 7: Ar11(L11)a11-(R11)b11]n11  Formula 1 Ar21(L21)a21-(R21)b21]n21  Formula 2 M(L1)n71(L2)n72.  Formula 7 The organic light-emitting device may have high efficiency and long lifespan and may show little change in the efficiency at an x-coordinate (CIEx) value of 0.21.

  一种有机发光器件包括：第一电极；第二电极；以及位于第一电极和第二电极之间的有机层，有机层包括发射层，其中发射层包括第一宿主和掺杂剂，第一宿主由式 1 和 2 中选出的一种表示，掺杂剂由式 7 表示： Ar11(L11)a11-(R11)b11]n11 式 1 Ar21(L21)a21-(R21)b21]n21 式 2 M(L1)n71(L2)n72.式 7 有机发光器件的效率高、寿命长，在 x 坐标（CIEx）值为 0.21 时，效率变化不大。
• QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0691966A1

  公开（公告）日：1996-01-17
• ORGANIC LIGHT-EMITTING DEVICE
  申请人：Samsung Display Co., Ltd.

  公开号：US20160111664A1

  公开（公告）日：2016-04-21

  An organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, wherein the emission layer includes a first host and a dopant, the first host is represented by one selected from Formulae 1 and 2, and the dopant is represented by Formula 7: Ar 11 (L 11 ) a11 -(R 11 ) b11 ] n11 Formula 1 Ar 21 (L 21 ) a21 -(R 21 ) b21 ] n21 Formula 2 M(L 1 ) n71 (L 2 ) n72 .  Formula 7 The organic light-emitting device may have high efficiency and long lifespan and may show little change in the efficiency at an x-coordinate (CIEx) value of 0.21.
• US5455252A
  申请人：——

  公开号：US5455252A

  公开（公告）日：1995-10-03
• [EN] QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS<br/>[FR] QUINOLEINES COMME INHIBITEURS DE LA PHOSPHODIESTERASE TYPE IV
  申请人：SYNTEX (U.S.A.) INC.

  公开号：WO1994022852A1

  公开（公告）日：1994-10-13

  (EN) Optionally 6,8-substituted quinolines of formula (I) wherein: R1 is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydroxy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; optionally substituted heterocycle, heterocycle-oxy, heterocycle-amino or heterocycle lower alkyl; and R2 is optionally substituted phenyl, or a pharmaceutically acceptable salt or N-oxide thereof, useful as anti-inflammatory agents, immunosuppressive agents, anti-allograft rejection agents, anti-graft-vs-host disease agents, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents, anti-autoimmune agents or analgetic agents.(FR) L'invention concerne des 6,8-quinoléines éventuellement substituées de la formule (I). Dans cette formule, R1 est un hydrogène, un alkyle inférieur, un cycloalkyle, un cycloalkyloxy, un cycloalkylamino, un cycloalkylalkyle inférieur, un alcoxy inférieur, un formyle, un hydroxyalkyle inférieur, un carboxyalkyle, un aryle éventuellement substitué, un aryloxy, un arylamino ou un arylalkyle inférieur, un hétérocycle éventuellement substitué, un hétérocycle-oxy, un hétérocycle-amino ou un hétérocycle-alkyle inférieur; et R2 est un phényle, éventuellement substitué. L'invention concerne également les sels de ces quinoléines acceptables sur le plan pharmaceutique ou leurs N-oxydes comme agents anti-inflammatoires, agents immunosuppresseurs, agents pour lutter contre le rejet d'allogreffes, agents contre les réactions du greffon contre l'hôte, agents antiallergiques (par exemple asthme, rhinite, et eczéma atopique), agents bronchodilatateurs, agents contre les affections auto-immunes ou agents analgésiques.